Oncology
Page 5 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
BriaCell Bria-OTS+ Shows Preserved Quality of Life in Phase 3 Metastatic Breast Cancer Trial at AACR 2026
BriaCell's Bria-OTS+ maintains quality of life in heavily pretreated metastatic breast cancer patients, with new biomarker data presented at AACR 2026.
EMA Accelerated Assessment Program: Impact on Oncology Drug Approval Timelines
The EMA's Accelerated Assessment Program significantly shortens oncology drug approval timelines, improving patient access to vital treatments such as Keytruda.
EU Clinical Trial Regulation: Streamlining Cross-Border Multi-State Studies
The EU Clinical Trial Regulation simplifies the process for conducting cross-border multi-state studies, improving the efficiency of drug XYZ for treating ABC.
EMA Conditional Approval Pathway: Linvoseltamab and Oncology Access in EU
This article delves into the EMA's Conditional Approval Pathway, focusing on Linvoseltamab and its impact on oncology access across the European Union.
CAR-T Therapies Cost-Effectiveness: EU HTA Bodies' Divergent Assessments
This article examines the varying assessments of CAR-T therapies' cost-effectiveness by EU HTA bodies, highlighting implications for cancer treatment.
MHRA vs EMA Oncology Approvals: Post-Brexit Divergence in 2026
This article examines the divergence in oncology drug approvals between MHRA and EMA in 2026, highlighting the impact on treatments like XYZ for cancer patients.
EU HTA Radioligand Therapy Assessment: Price, Access & Challenges
This article delves into the EU HTA's evaluation of radioligand therapy for prostate cancer, highlighting pricing, access issues, and the challenges in the healthcare landscape.
Adagene's Muzastotug Shows 66.7% Response Rate in Triple Combination Therapy for Hepatocellular Carcinoma at AACR 2026
Adagene's muzastotug demonstrates superior efficacy in combination therapy for liver cancer, achieving 66.7% response rate versus 32.5% control in Phase 1b/2 trial.
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
EMA's CHMP recommends conditional approval for Adstiladrin gene therapy to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
AIM ImmunoTech plans Phase 3 trial for Ampligen in pancreatic cancer, backed by positive Phase 2 data and orphan drug designations in US and Europe.
Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM
Beamion's zongertinib gains FDA accelerated approval for HER2-mutant NSCLC treatment following breakthrough therapy designation and NEJM publication.
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
TRI-611 molecular glue degrader gains FDA fast track status for ALK-positive NSCLC while Eisai's taletrectinib advances in Europe for ROS1+ lung cancer treatment.